OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/05/2026
Back to search
Official data from USPTO
TASLY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
08/05/2026
Trademark type
Combined
Nice classes
5
Filing date
08/16/2024
Registration date
01/27/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/27/2026
Last transaction
08/05/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
CN
Examiner
SUK, HAE P
Law office
L70
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of an outline of a shaded triangle with two cut-outs in the shape of horizontal bars crossing through the top half; a smaller shaded triangle appears inside; to the right of the triangles appears the literal element "TASLY".
Holders and representatives
Holders
Tasly Pharmaceutical Group Co., Ltd.
Representatives
Zhi Dong HSML, P. C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicine for human purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; chemico-pharmaceutical preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; biomedicine for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; herbs for medicinal purposes; medicines made of Chinese traditional medicinal herbs for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; capsules for medicinescapsules sold empty for pharmaceuticals; pharmaceutical preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; dietetic food and beverages adapted for medical use; bath preparationsmedicated; medical analgesic preparations; preparations for the treatment of burns; syrups for pharmaceutical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; vitamin preparations; sunburn preparations for pharmaceutical purposes; vaccines; detergents for medical purposes; disinfectants for hygiene purposes; digestives for pharmaceutical purposes; mineral water for medical purposes; mineral salts for medical purposes; purgatives; meal for pharmaceutical purposes; flour for pharmaceutical purposes; febrifuges; medicinal tea; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; anthelmintics; pharmaceutical gelatingelatin capsules sold empty for pharmaceuticals; germicides; greases for medical purposes; chemical preparations for the diagnosis of pregnancy; medicinal oilsother than essential oils; medicinal herbs; lotions for pharmaceutical purposesanti-bacterial hand washmedicated oral rinsegynecological vaginal wash for medical purposesanorectal wash for medical purposes; ointments for pharmaceutical purposessunburn ointmentsanti-inflammatory ointmentshemorrhoidal ointmentsfrostbite salve for pharmaceutical purposeseye ointments for medical use; pectin for pharmaceutical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; herbs teas for medicinal purposes; pharmaceutical preparations for skin care; pharmaceutical preparations for treating dandruff; first-aid boxesfilled; medicinal roots; medicinal herbal preparationsmedicated tonics for treating cardiovascular diseaseAMSheart failurecardiovascular and cerebrovascular disease; sedatives; soporifics; sugar for medical purposes; biological preparations for medical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; medical preparations for slimming purposes; by-products of the processing of cereals for dietetic or medical purposes; medicines for dental purposes; diagnostic preparations for medical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; medicinal drinks; ferments for pharmaceutical purposes; chemical reagents for medical or veterinary purposes; dietary fiber to aid digestion; enzyme preparations for medical purposes; amino acids for pharmaceutical purposes; mouthwashes for medical purposes; appetite suppressants for medical purposes; adjuvants for medical purposes; weight-reducing aidweight management supplements; pharmaceutical preparations for the treatment of sunburns; food supplementsantioxidants used for medicinal purposes; acne treatment preparation; medicinal herbal preparationslysine electuary for medicinal use; oral rehydration salts; medicinal liquormedicinal alcohol for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; medicinal herbal preparationsginseng electuary for medicinal use; ginseng for medicinal use; medicinal herbal preparationsmedlar; dietetic beverages adapted for medicinal purposesweight-reducing tea; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; nutritional food additives for medical purposes in the nature of natural food extracts derived from fishmeatvegetablesfruits; food for babies; milk powder for infants; air purifying preparations; medicated animal washes; veterinary preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis; medicated animal feed; biocides; vermin destroying preparations; sanitary towels; wadding for medical purposes; medical dressings; rubber for dental purposes; teeth filling material; diaper for pets; raw material medicinepilltabletcapsuleliquid dropsgranule for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS)diabetic retinopathyasthmacancercardiovascular and cerebrovascular diseasecoronary artery diseaseangina pectorismyocardial infarctioncoughdepressiondiabetes and its complicationsenteritisfebrisheadacheheart diseasehepatitishepatopathyhigh blood pressurehypertriglyceridemiahypercholesteremiacombined hyperlipidemiainsomniafatty liver diseaserespiratory tract infectionpsychosisrhinitis
Publications
History of USPTO decisions and trademark events.
31 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/05/2026
FIMP
FINAL DISPOSITION PROCESSED
08/05/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/27/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/27/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
01/27/2026
GPNX
NOTIFICATION PROCESSED BY IB
12/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/09/2025
PUBO
PUBLISHED FOR OPPOSITION
12/09/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/03/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/26/2025
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/25/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/11/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
11/11/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/11/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
11/11/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/11/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/28/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/28/2025
RFNT
REFUSAL PROCESSED BY IB
06/28/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/09/2025
RFRR
REFUSAL PROCESSED BY MPU
06/09/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/06/2025
CNRT
NON-FINAL ACTION WRITTEN
04/06/2025
DOCK
ASSIGNED TO EXAMINER
03/22/2025
MAFR
APPLICATION FILING RECEIPT MAILED
03/21/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/21/2025
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/21/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/06/2025
Continuous trademark protection
Get notified about every new filing that threatens TASLY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.